<DOC>
	<DOCNO>NCT00003519</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat woman breast cancer undergone surgery remove tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether doxorubicin/docetaxel ( DD ) improve disease-free survival overall survival compare doxorubicin/cyclophosphamide ( DC ) woman lymph node positive ( 1-3 positive node ) high risk lymph node negative breast cancer . II . Compare toxicity DD DC patient population . OUTLINE : This randomize study . Patients stratify node status ( positive v negative ) , menopause status ( pre- v post ) , estrogen receptor ( ER ) status/progesterone receptor ( PR ) status ( ER/PR unknown vs ER+/PR+ v ER+/PR- vs ER-/PR+ v ER-/PR- ) . Patients arm I receive doxorubicin IV plus docetaxel IV 1 hour every 3 week 4 treatment course . Patients arm II receive doxorubicin IV plus cyclophosphamide IV every 3 week 4 treatment course . All patient estrogen receptor progesterone receptor positive receive oral tamoxifen daily 5 year follow chemotherapy . Some patient may also receive radiotherapy follow chemotherapy . Patients follow every 3 month patient less 2 year study entry ; every 6 month patient 2-5 year study entry ; every 12 month patient great 5 year study entry . PROJECTED ACCRUAL : Approximately 2778 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm resectable adenocarcinoma breast Histologically positive lymph node ( 1 3 ) OR Lymph node negative high risk disease Tumor great 1.0 cm diameter May undergone axillary dissection least 6 node remove examined sentinel node biopsy Patients positive sentinel node biopsy receive axillary dissection No locally advance inflammatory metastatic breast cancer Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Adequate hepatic function Bilirubin great upper limit normal Renal : Adequate renal function Cardiovascular : Adequate cardiac function Normal MUGA echocardiogram Other : Not pregnant nursing Fertile patient must use effective barrier method contraception At least 5 year since prior invasive malignancy , except basal cell squamous cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy malignancy Endocrine therapy : No concurrent tamoxifen Up 4 week tamoxifen treatment malignancy allow Radiotherapy : No prior radiotherapy malignancy Prior radiotherapy breast ductal carcinoma situ allow Surgery : Tumor remove either modified radical mastectomy and/or segmental mastectomy plus axillary lymph node dissection sentinel node biopsy begin treatment protocol No great 84 day since last surgical procedure constitute completes definitive surgical therapy ( mastectomy ; axillary dissection/sentinel node biopsy ; resection primary site obtain negative margin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>